Newborn screening for spinal muscular atrophy

Article Properties
Cite
Nishio, Hisahide. “Newborn Screening for Spinal Muscular Atrophy”. The Lancet Child &Amp; Adolescent Health, vol. 7, no. 3, 2023, pp. 146-7, https://doi.org/10.1016/s2352-4642(22)00378-9.
Nishio, H. (2023). Newborn screening for spinal muscular atrophy. The Lancet Child &Amp; Adolescent Health, 7(3), 146-147. https://doi.org/10.1016/s2352-4642(22)00378-9
Nishio H. Newborn screening for spinal muscular atrophy. The Lancet Child & Adolescent Health. 2023;7(3):146-7.
Journal Categories
Medicine
Medicine (General)
Medicine
Pediatrics
Refrences
Title Journal Journal Categories Citations Publication Date
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA) PharmacoEconomics
  • Medicine: Medicine (General): Medical technology
  • Medicine: Therapeutics. Pharmacology
  • Social Sciences: Economic theory. Demography: Economics as a science
  • Medicine: Public aspects of medicine
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Social Sciences: Commerce: Business
  • Social Sciences: Economic theory. Demography: Economics as a science
 8 2022
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

 Nature Medicine
  • Science: Biology (General)
  • Science: Biology (General): Cytology
  • Medicine: Medicine (General)
  • Medicine: Medicine (General): Medical technology
  • Medicine: Medicine (General)
  • Science: Biology (General): Genetics
 101 2022
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go Neuromuscular Disorders
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
 94 2021
Spinal muscular atrophy: from rags to riches Neuromuscular Disorders
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
 13 2021
Advances in treatment of spinal muscular atrophy—new phenotypes, new challenges, new implications for care 2020
Refrences Analysis
Category Category Repetition
Medicine: Medicine (General)2
Medicine: Medicine (General): Medical technology2
Social Sciences: Economic theory. Demography: Economics as a science2
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system1
Medicine: Pediatrics1
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry1
Science: Biology (General)1
Science: Biology (General): Cytology1
Science: Biology (General): Genetics1
Medicine: Therapeutics. Pharmacology1
Medicine: Public aspects of medicine1
Medicine: Public aspects of medicine: Toxicology. Poisons1
Social Sciences: Commerce: Business1
The category Medicine: Medicine (General) 2 is the most frequently represented among the references in this article. It primarily includes studies from Seminars in Pediatric Neurology and Nature Medicine. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year